Government Contracts
Track federal awards and activity when available
Members-only details
CASIF Earnings Date & History
CASI Pharmaceuticals Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Oct 28, 2026 at 6:53 PM ET
CASI Pharmaceuticals Inc
Biotechnology
- Next earnings date
- Thursday, November 12, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.36
- Revenue estimate
- $0
Research beyond the earnings headline
What’s happening around CASIF?
Congressional Trading
Review purchases and sales when available, transaction and disclosure dates kept separate
Members-only details
Insider Transactions
Company insider purchase and sale filings when available
Members-only details
Support & Resistance Levels
Key technical levels on an interactive chart
Members-only details
Previews show an example layout only, not data for CASIF. Coverage varies by company.
CASIF earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Friday, May 15, 2026 | Q4 2025 | $-0.37 | $-0.80 | -115.7% | $7.2M |
| Friday, November 14, 2025 | Q3 2025 | $-0.41 | $-0.67 | -62.6% | $3.1M |
What the market is watching in CASIF's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, daily catalyst context and the members-only Weekly Watchlist are included.
Free by email
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
CASIF earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone, commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.